Support Centre
25 October 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

New application
Updating record

governing board
data set
letter of agreement
request information
guidance notes

[ ...Back to search results ] [ Print-friendly version ]
Comparative efficacy of albendazole and mebendazole against hookworm infection in Laos
DOI 10.1186/ISRCTN29126001
ClinicalTrials.gov identifier
EudraCT number
Public title Comparative efficacy of albendazole and mebendazole against hookworm infection in Laos
Scientific title Comparative efficacy of Albendazole and Mebendazole against hookworm infection: Randomised, controlled trial in schoolchildren in Khamkeuth district, Bolikhamxay province, Laos
Acronym AlMebLaos
Serial number at source N/A
Study hypothesis Albendazole (400 mg single dose) is more effective than mebendazole (500 mg single dose) in clearing hookworm infection.
Lay summary Not provided at time of registration
Ethics approval National Ethics Committee for Health Research, Vientiane, Laos. Date of approval: 01/04/2008 (ref: 170 /NECHR)
Study design Randomised controlled trial
Countries of recruitment Laos
Disease/condition/study domain Hookworm infection, and other intestinal helminth infections
Participants - inclusion criteria 1. School-child age between 6 and 16 years, both male and female
2. Hookworm infected (at least one of four egg-positive Kato-Katz slide, established on 2 stool samples)
Participants - exclusion criteria 1. Pregnancy
2. Severe illness
3. Non-consent
Anticipated start date 28/04/2008
Anticipated end date 30/05/2008
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 190
Interventions Mebendazole (500 mg, single dose, oral) vs albendzole (400 mg, single dose, oral) treatment.
Primary outcome measure(s) Hookworm parasite clearance (no hookworm egg in four Kato-Katz slides taken on two stool samples) at 21-23 days after treatment
Secondary outcome measure(s) Reduction of intensity of infection (reduction of mean number of hookworm eggs counted on four Kato-Katz slides taken on two different stool samples) at 21-23 days after treatment
Sources of funding Swiss National Science Foundation (Switzerland)
Trial website
Publications 1. 2012 results in http://www.ncbi.nlm.nih.gov/pubmed/22235353
Contact name Dr  Peter  Odermatt
  Address Swiss Tropical Institute
Department of Public Health and Epidemiology
Socinstrasse 57
  City/town Basel
  Zip/Postcode 4002
  Country Switzerland
Sponsor Swiss National Science Foundation (Switzerland)
  Address Wildhainweg 3
P.O. Box 8232
  City/town Bern
  Zip/Postcode 3001
  Country Switzerland
  Sponsor website: http://www.snf.ch
Date applied 25/04/2008
Last edited 02/05/2012
Date ISRCTN assigned 09/10/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.